Experts in gynecologic oncology review clinical cases in ovarian carcinoma, focusing on individualized approaches to the use of PARP inhibition in the first-line maintenance setting and key clinical trials.
EP. 1: Case 1: Stage IV, High-Grade, Serous Epithelial Ovarian Cancer
January 28th 2022Dr Thomas C. Krivak reviews a case of a 59-year-old woman who has stage IV, high-grade serous epithelial ovarian cancer and discusses ASCO and NCCN guideline recommendations for germline/somatic tumor testing.
Watch
EP. 3: Case 1: First-Line Maintenance Therapy in Advanced Ovarian Cancer
January 28th 2022John K. Chan, MD, leads a discussion on the role of first-line maintenance therapy for advanced ovarian cancer and the standard of care first-line maintenance approaches for a patient with gBRCA2-mutated disease.
Watch
EP. 8: Case 2: Stage III, High-Grade Serous Epithelial Ovarian Cancer
February 4th 2022Experts in gynecologic oncology review the case of a 71-year-old woman who is diagnosed with stage III, high-grade serous epithelial ovarian cancer, and comment on their approach to genetic testing in the frontline setting.
Watch
EP. 9: Case 2: Maintenance Strategies for Advanced Ovarian Cancer
February 4th 2022Thomas C. Krivak, MD; John K. Chan, MD; Cecelia H. Boardman, MD; and Ashley Farione, PA-C, review the optimal approach to maintenance therapeutic options for a patient with stage III, high-grade serous epithelial ovarian cancer.
Watch
EP. 10: Case 2: Monitoring Adverse Reactions With Niraparib Maintenance in Ovarian Cancer
February 4th 2022Cecelia H. Boardman, MD, John K. Chan, MD, and Thomas C. Krivak, MD, share strategies for monitoring adverse events and the optimal duration for niraparib maintenance therapy for a patient with advanced ovarian cancer.
Watch